JeanMarie Guenot: CEO of Amphivena Therapeutics Inc
Jeanmarie Guenot is a distinguished professional in the biotechnology and pharmaceutical industry. She has provided her services to different enterprises, both in the public and sector, for over two decades. She has ample skills in venture capital and business development. Guenot also has substantial experience in pharmaceutical R&D, project and alliance management and corporate and commercial development. Over the two decades, she has gotten a strong passion for creating and redeveloping companies. At the moment, JeanMarie Guenot is the CEO and President of Amphivena Therapeutics, Inc. Together, they focus on the creation of innovative bi-functional antibody therapies for hematologic malignancies.
Before her position at Amphivena, she was the President of SKS Ocular. Guenot founded this ophthalmic company, and it specialized on dry AMD. It was involved in the manufacturing and processing of therapeutics and ocular drug technologies for glaucoma, molecular degeneration, and ocular inflammation. In addition to that, JeanMarie served as a business advocate for Hoffman-La Roche in Shanghai and Basel. She was once the vice president of business and corporate development at PDL BioPharma. While working there, her primary roles were overseeing acquisitions and mergers, alliance management for the firm’s R&D and commercial product portfolios as well as licensing.
She negotiated and managed to close the Idec-PDL 50:50 deal. According to this deal, the two firms were to be involved in the developing and commercializing of a cancer drug. The coming together included three Phase-2 drug patients. It was an 800 million dollar transaction which encompassed 100 million dollar equity investment in PDL as well as therapeutic candidates. Biogen Idec and Hoffman-La Roche shared Ophthalmic which had been licensed by Guenot on guenotllc.com. She is highly skilled and experienced in ophthalmic diseases and auto-immune diseases.
JeanMarie Guenot’s career began at Atlas Venture. At the company, she managed venture capital investments and developed life science firms. Her scientific career began when she was appointed as the principal scientist at Hoffman-La Roche. Her role at the enterprise was developing drugs for metabolic and inflammation diseases. JeanMarie holds an MBA from the University of Pennsylvania and afterward got her Ph.D. from the University of California.
Learn more about Jeanmarie Guenot: http://www.businesswire.com/news/home/20170111005414/en/Maverick-Therapeutics-Takeda-Announce-Five-year-Collaboration-Advance